Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: Intermittent hormonal therapy (IHT) for prostate cancer aims to minimize treatment-related side-effects, to improve overall quality of life, to reduce the cost of care, and possibly to delay progression to castration-resistant prostate cancer. RECENT FINDINGS: With preclinical evidence suggesting a potential benefit for IHT in terms of time to androgen independence, with phase II and phase III studies producing optimistic results, and with the potential for reductions in cost and complications, IHT has become a popular modality of therapy around the globe. SUMMARY: In the near future intermittent therapy will have place in the treatment strategy in the management of prostate cancer, particularly on men with locally advanced disease.
No takes yet. Share an insight, caveat, or question.
Fernando Calais da Silva (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: